{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:24:24Z","timestamp":1788279864780,"version":"build-2803163510"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40119-022-00276-4","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T04:03:50Z","timestamp":1660536230000},"page":"473-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Therapeutic Usefulness of a Novel Calcium Channel Blocker Azelnidipine in the Treatment of Hypertension: A Narrative Review"],"prefix":"10.1007","volume":"11","author":[{"given":"C. Venkata S.","family":"Ram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"key":"276_CR1","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953\u20132041.","journal-title":"J Hypertens"},{"key":"276_CR2","unstructured":"World Health Organization. Hypertension Fact Sheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension. Accessed 17 May 2022."},{"key":"276_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41371-020-0349-x","volume":"34","author":"SN Shah","year":"2020","unstructured":"Shah SN, Munjal YP, Kamath SA, et al. Indian guidelines on hypertension-IV (2019). J Hum Hypertens. 2020;34:745\u201358.","journal-title":"J Hum Hypertens"},{"key":"276_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ihj.2019.09.012","volume":"71","author":"S Ramakrishnan","year":"2019","unstructured":"Ramakrishnan S, Zachariah G, Gupta K, et al. Prevalence of hypertension among Indian adults: results from the great India blood pressure survey. Indian Heart J. 2019;71:309\u201313.","journal-title":"Indian Heart J"},{"key":"276_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ihj.2018.02.003","volume":"70","author":"R Gupta","year":"2018","unstructured":"Gupta R, Xavier D. Hypertension: the most important non communicable disease risk factor in India. Indian Heart J. 2018;70:565\u201372.","journal-title":"Indian Heart J"},{"key":"276_CR6","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1097\/HJH.0000000000000146","volume":"32","author":"R Anchala","year":"2014","unstructured":"Anchala R, Kannuri NK, Pant H, et al. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens. 2014;32:1170\u20137.","journal-title":"J Hypertens"},{"key":"276_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/1074248414555403","volume":"20","author":"G Tocci","year":"2015","unstructured":"Tocci G, Battistoni A, Passerini J, et al. Calcium channel blockers and hypertension. J Cardiovasc Pharmacol Ther. 2015;20:121\u201330.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"276_CR8","unstructured":"McKeever RG, Hamilton RJ. Calcium channel blockers. Treasure Island (FL): StatPearls; 2022 Jan. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482473\/. Accessed 13 May 2022."},{"key":"276_CR9","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/hr.2015.106","volume":"38","author":"M Abe","year":"2015","unstructured":"Abe M, Soma M. Multifunctional L\/N- and L\/T-type calcium channel blockers for kidney protection. Hypertens Res. 2015;38:804\u20136.","journal-title":"Hypertens Res"},{"key":"276_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1751-7176.2011.00513.x","volume":"13","author":"WJ Elliott","year":"2011","unstructured":"Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens (Greenwich). 2011;13:687\u20139.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"276_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0021-5198(19)40137-6","volume":"51","author":"K Oizumi","year":"1989","unstructured":"Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura T. Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker. Jpn J Pharmacol. 1989;51:57\u201364.","journal-title":"Jpn J Pharmacol"},{"key":"276_CR12","unstructured":"DrugBank. Azelnidipine. https:\/\/go.drugbank.com\/drugs\/DB09230. Accessed 8 Feb 2022."},{"key":"276_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1291\/hypres.26.201","volume":"26","author":"K Kuramoto","year":"2003","unstructured":"Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res. 2003;26:201\u20138.","journal-title":"Hypertens Res"},{"key":"276_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1254\/fpj.122.539","volume":"122","author":"T Sada","year":"2003","unstructured":"Sada T, Saito H. [Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker]. Nihon Yakurigaku Zasshi. 2003;122:539\u201347.","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"276_CR15","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/hr.2011.74","volume":"34","author":"K Hayashi","year":"2011","unstructured":"Hayashi K. L-\/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers. Hypertens Res. 2011;34:910\u20132.","journal-title":"Hypertens Res"},{"key":"276_CR16","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1097\/HJH.0000000000000270","volume":"32","author":"J Inomata","year":"2014","unstructured":"Inomata J, Murai H, Kaneko S, et al. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension. J Hypertens. 2014;32:1898\u2013904.","journal-title":"J Hypertens"},{"key":"276_CR17","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.2165\/00003495-200363230-00004","volume":"63","author":"K Wellington","year":"2003","unstructured":"Wellington K, Scott LJ. Azelnidipine. Drugs. 2003;63:2613\u201321.","journal-title":"Drugs"},{"key":"276_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejphar.2008.12.041","volume":"605","author":"T Isaka","year":"2009","unstructured":"Isaka T, Ikeda K, Takada Y, Inada Y, Tojo K, Tajima N. Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R. Eur J Pharmacol. 2009;605:49\u201352.","journal-title":"Eur J Pharmacol"},{"key":"276_CR19","first-page":"371","volume":"32","author":"T Isaka","year":"2011","unstructured":"Isaka T, Yahashi T, Sakamoto M, Sakamoto N, Ikeda K, Tojo K. Azelnidipine decreased plasma aldosterone and plasminogen activator inhibitor type 1 levels in the hypertensive patients with type 2 diabetes mellitus-the Jikei Azelnidipine study in the patients with Hypertension and Diabetes Mellitus (JAz-HDM). Ther Res. 2011;32:371\u201381.","journal-title":"Ther Res"},{"key":"276_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/hr.2009.179","volume":"33","author":"M Watanabe","year":"2010","unstructured":"Watanabe M, Hirano T, Okamoto S, Shiraishi S, Tomiguchi S, Uchino M. Azelnidipine, a long-acting calcium channel blocker, could control hypertension without decreasing cerebral blood flow in post-ischemic stroke patients. A 123I-IMP SPECT follow-up study. Hypertens Res. 2010;33:43\u20138.","journal-title":"Hypertens Res"},{"key":"276_CR21","first-page":"309","volume":"11","author":"BL Chen","year":"2015","unstructured":"Chen BL, Zhang YZ, Luo JQ, Zhang W. Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. Ther Clin Risk Manag. 2015;11:309\u201318.","journal-title":"Ther Clin Risk Manag"},{"key":"276_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1254\/jjp.53.264","volume":"53","author":"K Oizumi","year":"1990","unstructured":"Oizumi K, Miyamoto M, Koike H. Antihypertensive effect of CS-905, a novel dihydropyridine calcium blocker, in conscious hypertensive dogs. Jpn J Pharmacol. 1990;53:264\u20136.","journal-title":"Jpn J Pharmacol"},{"key":"276_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1254\/jjp.54.1","volume":"54","author":"K Oizumi","year":"1990","unstructured":"Oizumi K, Nishino H, Miyake S, et al. Hemodynamic changes following long-term administration of CS-905, a novel dihydropyridine calcium blocker, in conscious SHR. Jpn J Pharmacol. 1990;54:1\u20136.","journal-title":"Jpn J Pharmacol"},{"key":"276_CR24","first-page":"1505","volume":"15","author":"A Hirai","year":"1999","unstructured":"Hirai A, Terano T, Saito Y. Efficacy and safety of CS-905 (azelnidipine) combination therapy on essential hypertension. Rinsho Iyaku. 1999;15:1505\u201345.","journal-title":"Rinsho Iyaku"},{"key":"276_CR25","first-page":"869","volume":"15","author":"K Yoshinaga","year":"1999","unstructured":"Yoshinaga K, Iimura O, Abe K, Ishii T, Saruta Y, Ogiwara T. Efficacy and safety of CS-905 (azelnidipine) in patients with essential hypertension: early phase II clinical study (pre-pilot and pilot I). Rinsho Iyaku. 1999;15:869\u201390.","journal-title":"Rinsho Iyaku"},{"key":"276_CR26","first-page":"891","volume":"15","author":"K Yoshinaga","year":"1999","unstructured":"Yoshinaga K, Iimura O, Abe K, Ishii T, Saruta Y, Ogiwara T. Efficacy and safety of CS-905 (azelnidipine) in patients with essential hypertension: early phase II clinical study (pilot II). Rinsho Iyaku. 1999;15:891\u2013905.","journal-title":"Rinsho Iyaku."},{"key":"276_CR27","first-page":"907","volume":"15","author":"K Yoshinaga","year":"1999","unstructured":"Yoshinaga K, Iimura O, Abe K, Ishii T, Saruta Y, Ogiwara T. Late phase II study of CS-905, azelnidipine, in patients with essential hypertension: a multi-center, double-blind comparative study for evaluation of optimal dose. Rinsho Iyaku. 1999;15:907\u201342.","journal-title":"Rinsho Iyaku"},{"key":"276_CR28","first-page":"943","volume":"15","author":"K Yoshinaga","year":"1999","unstructured":"Yoshinaga K, Iimura O, Abe K, Ishii T, Saruta Y, Ogiwara T. Efficacy and safety of CS-905 (azelnidipine) monotherapy on essential hypertension in the long-term treatment. Rinsho Iyaku. 1999;15:943\u201383.","journal-title":"Rinsho Iyaku"},{"key":"276_CR29","first-page":"671","volume":"16","author":"K Yoshinaga","year":"2000","unstructured":"Yoshinaga K, Iimura O, Abe K, et al. Phase III clinical trial of CS-905 (azelnidipine) in patients with essential hypertension. Rinsho Iyaku. 2000;16:671\u2013739.","journal-title":"Rinsho Iyaku"},{"key":"276_CR30","first-page":"741","volume":"16","author":"K Yoshinaga","year":"2000","unstructured":"Yoshinaga K, Hirai A, Yamakado M. Evaluation of safety profile of CS-905, azelnidipine, in clinical trials of hypertension. Rinsho Iyaku. 2000;16:741\u201362.","journal-title":"Rinsho Iyaku"},{"key":"276_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1254\/jjp.76.369","volume":"76","author":"K Satoh","year":"1998","unstructured":"Satoh K, Yamamoto A, Hoshi K, Ichihara K. Effects of azelnidipine, a dihydropyridine calcium antagonist, on myocardial stunning in dogs. Jpn J Pharmacol. 1998;76:369\u201376.","journal-title":"Jpn J Pharmacol"},{"key":"276_CR32","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/ajh\/7.7.637","volume":"7","author":"Y Yagil","year":"1994","unstructured":"Yagil Y, Miyamoto M, Frasier L, Oizumi K, Koike H. Effects of CS-905, a novel dihydropyridine calcium channel blocker, on arterial pressure, renal excretory function, and inner medullary blood flow in the rat. Am J Hypertens. 1994;7:637\u201346.","journal-title":"Am J Hypertens"},{"key":"276_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0021-5198(19)40076-0","volume":"51","author":"K Oizumi","year":"1989","unstructured":"Oizumi K, Nishino H, Miyamoto M, Fukushige J, Fukami M, Koike H. Beneficial renal effects of CS-905, a novel dihydropyridine calcium blocker, in SHR. Jpn J Pharmacol. 1989;51:501\u20138.","journal-title":"Jpn J Pharmacol"},{"key":"276_CR34","first-page":"451","volume":"15","author":"K Tomita","year":"1999","unstructured":"Tomita K, Nonoguchi H, Marumo F. Effect of CS-905 (azelnidipine) on renal function in essential hypertension. Rinsho Iyaku. 1999;15:451\u201363.","journal-title":"Rinsho Iyaku"},{"key":"276_CR35","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1291\/hypres.31.2147","volume":"31","author":"Y Kimura","year":"2008","unstructured":"Kimura Y, Kitagawa K, Oku N, et al. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions. Hypertens Res. 2008;31:2147\u201354.","journal-title":"Hypertens Res"},{"key":"276_CR36","first-page":"355","volume":"16","author":"M Yamakado","year":"2000","unstructured":"Yamakado M. Clinical study of CS-905 (azelnidipine) on anti-atherosclerotics and protective effect of renal function in patients with hypertension. Rinsho Iyaku. 2000;16:355\u201373.","journal-title":"Rinsho Iyaku"},{"key":"276_CR37","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1253\/circj.CJ-11-0141","volume":"75","author":"T Kojima","year":"2011","unstructured":"Kojima T, Miyauchi K, Yokoyama T, et al. Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J). Circ J. 2011;75:1071\u20139.","journal-title":"Circ J"},{"key":"276_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/10641960903254414","volume":"32","author":"H Komoda","year":"2010","unstructured":"Komoda H, Inoue T, Node K. Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker. Clin Exp Hypertens. 2010;32:121\u20138.","journal-title":"Clin Exp Hypertens"},{"key":"276_CR39","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/j.1476-5381.2011.01599.x","volume":"165","author":"T Ohyama","year":"2012","unstructured":"Ohyama T, Sato K, Kishimoto K, et al. Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence. Br J Pharmacol. 2012;165:1173\u201387.","journal-title":"Br J Pharmacol"},{"key":"276_CR40","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1507\/endocrj.EJ15-0273","volume":"62","author":"F Tatsumi","year":"2015","unstructured":"Tatsumi F, Kaneto H, Hashiramoto M, et al. Anti-hypertensive azelnidipine preserves insulin signaling and glucose uptake against oxidative stress in 3T3-L1 adipocytes. Endocr J. 2015;62:741\u20137.","journal-title":"Endocr J"},{"key":"276_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1475-2840-10-79","volume":"10","author":"K Fukao","year":"2011","unstructured":"Fukao K, Shimada K, Hiki M, et al. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function\u2013a crossover trial (AGENT). Cardiovasc Diabetol. 2011;10:79.","journal-title":"Cardiovasc Diabetol"},{"key":"276_CR42","first-page":"977","volume":"34","author":"D Li","year":"2013","unstructured":"Li D, Dong W, Chen Y. Azelnidipine in treatment of mild-moderate essential hypertension: a clinical trial. Jie Fang Jun Yi Xue Yuan Xue Bao. 2013;34:977\u201380.","journal-title":"Jie Fang Jun Yi Xue Yuan Xue Bao"},{"key":"276_CR43","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1291\/hypres.29.767","volume":"29","author":"T Yamagishi","year":"2006","unstructured":"Yamagishi T. Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine. Hypertens Res. 2006;29:767\u201373.","journal-title":"Hypertens Res"},{"key":"276_CR44","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3109\/10641961003628510","volume":"32","author":"X Zhao","year":"2010","unstructured":"Zhao X, Wu F, Jia S, et al. Azelnidipine and amlodipine: a comparison of their effects and safety in a randomized double-blinded clinical trial in Chinese essential hypertensive patients. Clin Exp Hypertens. 2010;32:372\u20136.","journal-title":"Clin Exp Hypertens"},{"key":"276_CR45","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/FJC.0b013e31819f1be1","volume":"53","author":"M Fujisawa","year":"2009","unstructured":"Fujisawa M, Yorikane R, Chiba S, Koike H. Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine. J Cardiovasc Pharmacol. 2009;53:325\u201332.","journal-title":"J Cardiovasc Pharmacol"},{"key":"276_CR46","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/echo.12548","volume":"31","author":"H Motoki","year":"2014","unstructured":"Motoki H, Koyama J, Izawa A, et al. Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy. Echocardiography. 2014;31:1230\u20138.","journal-title":"Echocardiography"},{"key":"276_CR47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2147\/VHRM.S21991","volume":"7","author":"T Takami","year":"2011","unstructured":"Takami T, Saito Y. Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study. Vasc Health Risk Manag. 2011;7:383\u201390.","journal-title":"Vasc Health Risk Manag"},{"key":"276_CR48","first-page":"2797","volume":"22","author":"S Yi","year":"2013","unstructured":"Yi S, Wu Z, Shao N, Wang Y, Feng W. The influence of azelnidipine on left ventricular diastolic function in hypertensive patients. Xian Dai Zhong Xi Yi Jie He Za Zhi. 2013;22:2797\u20138.","journal-title":"Xian Dai Zhong Xi Yi Jie He Za Zhi"},{"key":"276_CR49","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1152\/advan.00065.2013","volume":"37","author":"CD Johnson","year":"2013","unstructured":"Johnson CD, Roe S, Tansey EA. Investigating autonomic control of the cardiovascular system: a battery of simple tests. Adv Physiol Educ. 2013;37:401\u20134.","journal-title":"Adv Physiol Educ"},{"key":"276_CR50","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1161\/CIRCRESAHA.114.302589","volume":"114","author":"VG Florea","year":"2014","unstructured":"Florea VG, Cohn JN. The autonomic nervous system and heart failure. Circ Res. 2014;114:1815\u201326.","journal-title":"Circ Res"},{"key":"276_CR51","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/hr.2016.94","volume":"39","author":"Y Koike","year":"2016","unstructured":"Koike Y, Kawabe T, Nishihara K, Iwane N, Hano T. Effects of azelnidipine and amlodipine on exercise-induced sympathoexcitation assessed by pupillometry in hypertensive patients. Hypertens Res. 2016;39:863\u20137.","journal-title":"Hypertens Res"},{"key":"276_CR52","first-page":"698","volume":"57","author":"T Nada","year":"2007","unstructured":"Nada T, Nomura M, Koshiba K, Kawano T, Mikawa J, Ito S. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung. 2007;57:698\u2013704.","journal-title":"Arzneimittelforschung"},{"key":"276_CR53","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1536\/ihj.17-024","volume":"59","author":"S Kiuchi","year":"2018","unstructured":"Kiuchi S, Hisatake S, Kabuki T, et al. Effect of switching from cilnidipine to azelnidipine on cardiac sympathetic nerve function in patients with heart failure preserved ejection fraction. Int Heart J. 2018;59:120\u20135.","journal-title":"Int Heart J"},{"key":"276_CR54","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jjcc.2008.01.005","volume":"51","author":"J Yamada","year":"2008","unstructured":"Yamada J, Tomiyama H, Matsumoto C, Yoshida M, Shiina K, Yamashina A. Effects of azelnidipine on the autonomic functions and its influence on arterial stiffness and endothelial functions. J Cardiol. 2008;51:114\u201320.","journal-title":"J Cardiol"},{"key":"276_CR55","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/j.jss.2011.02.039","volume":"169","author":"M Bagheri","year":"2011","unstructured":"Bagheri M, Jahromi BM, Mirkhani H, et al. Azelnidipine, a new calcium channel blocker, promotes skin wound healing in diabetic rats. J Surg Res. 2011;169:e101\u20137.","journal-title":"J Surg Res"},{"key":"276_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125519","volume":"10","author":"M Takihata","year":"2015","unstructured":"Takihata M, Nakamura A, Kondo Y, Kawasaki S, Kimura M, Terauchi Y. Comparison of azelnidipine and trichlormethiazide in Japanese type 2 diabetic patients with hypertension: the COAT randomized controlled trial. PLoS ONE. 2015;10: e0125519.","journal-title":"PLoS ONE"},{"key":"276_CR57","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1291\/hypres.31.1499","volume":"31","author":"S Katayama","year":"2008","unstructured":"Katayama S, Kawamori R, Iwamoto Y, Saito I, Kuramoto K. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of < 130\/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study. Hypertens Res. 2008;31:1499\u2013508.","journal-title":"Hypertens Res"},{"key":"276_CR58","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","volume":"37","author":"JR Sowers","year":"2001","unstructured":"Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053\u20139.","journal-title":"Hypertension"},{"key":"276_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40265-019-1064-1","volume":"79","author":"D Pugh","year":"2019","unstructured":"Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. Drugs. 2019;79:365\u201379.","journal-title":"Drugs"},{"key":"276_CR60","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1161\/01.HYP.0000091371.53502.D3","volume":"42","author":"K Masuo","year":"2003","unstructured":"Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474\u201380.","journal-title":"Hypertension"},{"key":"276_CR61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jch.12026","volume":"15","author":"O Turak","year":"2013","unstructured":"Turak O, Ozcan F, Tok D, et al. Serum uric acid, inflammation, and nondipping circadian pattern in essential hypertension. J Clin Hypertens (Greenwich). 2013;15:7\u201313.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"276_CR62","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3109\/10641963.2013.846359","volume":"36","author":"S Miyazaki","year":"2014","unstructured":"Miyazaki S, Hamada T, Hirata S, et al. Effects of azelnidipine on uric acid metabolism in patients with essential hypertension. Clin Exp Hypertens. 2014;36:447\u201353.","journal-title":"Clin Exp Hypertens"},{"key":"276_CR63","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1093\/ndt\/gfp407","volume":"24","author":"S Fujimoto","year":"2009","unstructured":"Fujimoto S, Satoh M, Nagasu H, Horike H, Sasaki T, Kashihara N. Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats. Nephrol Dial Transplant. 2009;24:3651\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"276_CR64","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1097\/01.ASN.0000132473.50966.14","volume":"15","author":"EM Freel","year":"2004","unstructured":"Freel EM, Connell JM. Mechanisms of hypertension: the expanding role of aldosterone. J Am Soc Nephrol. 2004;15:1993\u20132001.","journal-title":"J Am Soc Nephrol"},{"key":"276_CR65","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389:1238\u201352.","journal-title":"Lancet"},{"key":"276_CR66","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2016.12.004","volume":"69","author":"R Saran","year":"2017","unstructured":"Saran R, Robinson B, Abbott KC, et al. US renal data system 2016 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2017;69:A7\u20138.","journal-title":"Am J Kidney Dis"},{"key":"276_CR67","doi-asserted-by":"publisher","first-page":"F1563","DOI":"10.1152\/ajprenal.90302.2008","volume":"295","author":"D Verzola","year":"2008","unstructured":"Verzola D, Gandolfo MT, Gaetani G, et al. Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy. Am J Physiol Renal Physiol. 2008;295:F1563\u201373.","journal-title":"Am J Physiol Renal Physiol"},{"key":"276_CR68","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/MAJ.0b013e318065c254","volume":"333","author":"T Nakamura","year":"2007","unstructured":"Nakamura T, Sugaya T, Kawagoe Y, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 2007;333:321\u20136.","journal-title":"Am J Med Sci"},{"key":"276_CR69","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/hr.2011.67","volume":"34","author":"M Abe","year":"2011","unstructured":"Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertens Res. 2011;34:935\u201341.","journal-title":"Hypertens Res"},{"key":"276_CR70","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13098-015-0073-9","volume":"7","author":"K Tawaramoto","year":"2015","unstructured":"Tawaramoto K, Kaneto H, Hashiramoto M, et al. Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in type 2 diabetes (BOAT2 study). Diabetol Metab Syndr. 2015;7:80.","journal-title":"Diabetol Metab Syndr"},{"key":"276_CR71","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1291\/hypres.31.1147","volume":"31","author":"S Ogawa","year":"2008","unstructured":"Ogawa S, Mori T, Nako K, Ito S. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res. 2008;31:1147\u201355.","journal-title":"Hypertens Res"},{"issue":"1","key":"276_CR72","first-page":"67","volume":"14","author":"AL Wang","year":"2017","unstructured":"Wang AL, Iadecola C, Wang G. New generations of dihydropyridines for treatment of hypertension. J Geriatr Cardiol. 2017;14(1):67\u201372.","journal-title":"J Geriatr Cardiol"},{"issue":"2","key":"276_CR73","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/jdi.12003","volume":"4","author":"H Abe","year":"2013","unstructured":"Abe H, Mita T, Yamamoto R, Komiya K, et al. Comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: a pilot study. J Diabetes Investig. 2013;4(2):202\u20135.","journal-title":"J Diabetes Investig"},{"issue":"3","key":"276_CR74","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40268-017-0191-y","volume":"17","author":"Y Nishida","year":"2017","unstructured":"Nishida Y, Takahashi Y, Tezuka K, et al. Comparative effect of calcium channel blockers on glomerular function in hypertensive patients with diabetes mellitus. Drugs R D. 2017;17(3):403\u201312.","journal-title":"Drugs R D"},{"key":"276_CR75","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/HJH.0b013e328340d76f","volume":"29","author":"DJ Trevisol","year":"2011","unstructured":"Trevisol DJ, Moreira LB, Kerkhoff A, Fuchs SC, Fuchs FD. Health-related quality of life and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2011;29:179\u201388.","journal-title":"J Hypertens"},{"key":"276_CR76","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1161\/CIRCULATIONAHA.114.008729","volume":"133","author":"D Prabhakaran","year":"2016","unstructured":"Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in India: current epidemiology and future directions. Circulation. 2016;133:1605\u201320.","journal-title":"Circulation"},{"key":"276_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mjafi.2019.12.005","volume":"76","author":"A Sreeniwas Kumar","year":"2020","unstructured":"Sreeniwas Kumar A, Sinha N. Cardiovascular disease in India: a 360 degree overview. Med J Armed Forces India. 2020;76:1\u20133.","journal-title":"Med J Armed Forces India"},{"key":"276_CR78","unstructured":"HelpAge global network. Ageing population in India. https:\/\/ageingasia.org\/ageing-population-india\/. Accessed 18 May 2022."},{"key":"276_CR79","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40268-013-0006-8","volume":"13","author":"K Kario","year":"2013","unstructured":"Kario K, Sato Y, Shirayama M, et al. Inhibitory effects of azelnidipine tablets on morning hypertension. Drugs R D. 2013;13:63\u201373.","journal-title":"Drugs R D"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-022-00276-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-022-00276-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-022-00276-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T02:27:11Z","timestamp":1668306431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-022-00276-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["276"],"URL":"https:\/\/doi.org\/10.1007\/s40119-022-00276-4","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,13]]},"assertion":[{"value":"30 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}